Business Context and Reporting Period
This Form 8-K Current Report, dated January 8, 2026, covers the corporate rebranding of Salarius Pharmaceuticals, Inc. The Company officially changed its legal name to Decoy Therapeutics Inc. effective January 8, 2026. This change was effected via a Certificate of Amendment filed with the Delaware Secretary of State and did not require a stockholder vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and branding changes rather than financial performance.
Material Changes
- Legal Name Change: Changed from "Salarius Pharmaceuticals, Inc." to "Decoy Therapeutics Inc."
- Trading Symbol Change: Common stock ceased trading under the ticker "SLRX" and began trading under the new ticker "DCOY" on the Nasdaq Capital Market.
- Bylaws Amendment: The Board approved the Second Amended and Restated Bylaws to reflect the new corporate name.
- Website Launch: A new corporate website, decoytx.com, was launched to host investor relations information.
Guidance, Outlook, and Risks
The filing references forward-looking statements contained in the accompanying press release (Exhibit 99.1). Management notes that these statements are based on current expectations and are not guarantees of future performance. Actual results may differ materially due to risks and uncertainties. The filing explicitly states that the name change does not affect the rights of the Company's stockholders.
Investor Verification Checklist
- Verify the new ticker symbol "DCOY" on the Nasdaq Capital Market.
- Confirm the new corporate website address: decoytx.com.
- Review the Second Amended and Restated Bylaws (Exhibit 3.2) for any operational changes beyond the name update.
- Check the press release (Exhibit 99.1) for strategic rationale behind the rebranding.